Skip Navigation

European Heart Journal 2000 21(14):1116; doi:10.1053/euhj.2000.2142
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brugada, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brugada, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Magnesium: an antiarrhythmic drug, but only against very specific arrhythmias

P. Brugada

Cardiovascular Research and Training Institute, Aalst, Belgium

References

  1. Kulick DL, Hong R, Ryzen E. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of cardiac disease. Am Heart J. 1988;115:367–373[CrossRef][Web of Science][Medline]
  2. DiCarlo LA, Morady F, Buitleir M, Krol RB, Schurig L, Annesley TM. Effects of magnesium sulphate on cardiac conduction and refractoriness in humans. J Am Coll Cardiol. 1986;7:1356–1362[Abstract]
  3. Reinhart R, Marx J, Broste S, Haas R. Myocardial magnesium: relation to laboratory and clinical variables in patients undergoing cardiac surgery. J Am Coll Cardiol. 1991;17:651–656[Abstract]
  4. Tzivoni A, Keren. Suppression of ventricular arrhythmias by magnesium. Am J Cardiol. 1990;65:1397–1399[CrossRef][Web of Science][Medline]
  5. Frick M, Darpö B, Östergren J, Rosenqvist M. The effect of oral magnesium, alone or as an adjuvant to sotalol, after cardioversion in patients with persistent atrial fibrillation. Eur Heart J. 2000;21:1177–1185[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brugada, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brugada, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?